Levocetirizine/montelukast

Drug Profile

Levocetirizine/montelukast

Alternative Names: HCP 1102; Montelukast/levocetirizine

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Acetates; Antiallergics; Antiasthmatics; Nonsedating antihistamines; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinitis; Perennial allergic rhinitis

Most Recent Events

  • 01 Jul 2015 Hanmi Pharmaceutical completes a phase III trial in Allergic rhinitis (in patients with mild or moderate asthma) in South Korea (PO) (NCT01640535)
  • 13 May 2015 Phase-III development for Perennial allergic rhinitis is ongoing in South Korea
  • 04 Apr 2013 Hanmi Pharmaceutical Company completes a phase III trial in Perennial allergic rhinitis in South Korea (NCT01640535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top